Mohammad Amjad Hussain


  • MSc (Area): Clinical Biochemistry


I did my masters’ in Clinical Biochemistry from the University of Kashmir and BSc in Biochemistry, Chemistry, and Zoology. I am passionate about Biological science, particularly Molecular Biology and Oncology, as one of my core subjects in my Master’s was the same. During my 4th semester of MSc, I underwent short-term training in Cancer biology and genetics labs at Sher-e-Kashmir Institute of Sciences (SKIMS), a renowned State hospital. In this dissertation, my main focus was to correlate the gene (DCC rs714 A>G) polymorphism in Gallbladder carcinoma in Kashmir Valley.

Awards/ Honors

  • Qualified GATE exam 2020








Research Interest/Area

Molecular Biology, DNA replication, repair and recombination, Non-Homologous end joining (NHEJ), Homologous Recombination (HR), Translesion synthesis, Chemotherapy


Thrombopoietin (THPO) and its receptor c-MPL are known for their role in regulating hematopoiesis. C-MPL has two isoforms, full-length MPL (MPL-FL) and trunked MPL (MPL-TR). These two isomers of c-Mpl play a vital role in megakaryocyte development and hematopoiesis. Over-expression of Mpl-TR decreases HSC function in a dominant-negative manner, most likely due to decreased signaling from Thpo in these cells. In diseases such as Acute Myeloid Leukemia (AML), the leukemic cells express a high level of c-MPL, which supports enhanced proliferation and survival. Currently, we are trying to characterize the expression of c-MPL and its isoforms in various AML cell lines and to understand the molecular mechanisms underlining the survival of AML cells. Also, the ASO approach to alter c-MPL splicing would have the advantage of high specificity. It would exploit a novel therapeutic strategy for diseases having treatments with low effectiveness and high toxicities. Alternate splicing using antisense oligonucleotides (ASOs) has been successfully performed in diseases involving genes such as DMD, LMNA, and FKTN.